SCHEMBL1019302

SCHEMBL1019302

O=C(Cl)c1ccc2occc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 8/20 0.57
WNT3A P56704 8/20 0.57
HTR1B P28222 1/20 0.55
NAMPT P43490 1/20 0.48
CYP2A6 P11509 2/20 0.47
CHRNA7 P36544 2/20 0.46
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46
IDO1 P14902 2/20 0.45
HTR3E A5X5Y0 1/20 0.45
HTR3B O95264 1/20 0.45
CYP2D6 P10635 1/20 0.45
HTR3A P46098 1/20 0.45
HTR3D Q70Z44 1/20 0.45
HTR3C Q8WXA8 1/20 0.45
AR P10275 1/20 0.43
EPM2A O95278 1/20 0.42
PTPRC P08575 1/20 0.42
PTPN6 P29350 1/20 0.42
CDC14A Q9UNH5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20617027 0.85 HTR1B (0.55) CTNNB1WNT3AHTR1BCYP2A6CHRNA7
SCHEMBL663873 0.82 CTNNB1 (0.63) CTNNB1WNT3AHTR1BNAMPTCYP2A6
SCHEMBL4318315 0.82 CTNNB1 (0.58) CTNNB1WNT3AHTR1BNAMPTCYP2A6
SCHEMBL29987426 0.82 CTNNB1 (0.63) CTNNB1WNT3AHTR1BNAMPTCYP2A6
SCHEMBL28431104 0.81 CTNNB1 (0.59) CTNNB1WNT3AHTR1BNAMPTCYP2A6
SCHEMBL3441414 0.81 AR (0.61) CTNNB1WNT3AHTR1BNAMPTCYP2A6
SCHEMBL103953 0.81 CTNNB1 (0.59) CTNNB1WNT3AHTR1BNAMPTCYP2A6
SCHEMBL11243027 0.79 CTNNB1 (0.59) CTNNB1WNT3AHTR1BNAMPTCYP2A6
SCHEMBL13389559 0.78 CTNNB1 (0.54) CTNNB1WNT3AHTR1BNAMPTCYP2A6
SCHEMBL22471326 0.78 HTR1B (0.56) CTNNB1WNT3AHTR1BNAMPTCYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114014824-B Application of heterocyclic compound 上海科技大学 2023-06-13 CN disclosed
US-11246862-B2 Process for the preparation of lifitegrast MANKIND PHARMA LTD. (IN) 2022-02-15 US disclosed
US-20200306242-A1 NOVEL PROCESS FOR THE PREPARATION OF LIFITEGRAST MANKIND PHARMA LTD. (IN) 2020-10-01 US disclosed
EP-3233087-B1 GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS AXOVANT SCIENCES GMBH (DE) 2019-10-02 EP disclosed
WO-2019073325-A1 NOVEL PROCESS FOR THE PREPARATION OF LIFITEGRAST MANKIND PHARMA LTD. (IN) 2019-04-18 WO disclosed
US-10183938-B2 Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors AXOVANT SCIENCES GMBH (CH) 2019-01-22 US disclosed
US-20170369486-A1 GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS AXOVANT SCIENCES GMBH (CH) 2017-12-28 US disclosed
US-9403789-B2 Benzofuran-containing amino acid inhibitors of cytochrome P450 SEQUOIA PHARMACEUTICALS, INC. (US) 2016-08-02 US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-8772327-B2 Phenylpropionic acid derivative and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2014-07-08 US disclosed
US-7183281-B2 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2007-02-27 US disclosed
US-20060293332-A1 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2006-12-28 US disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed
WO-2006089100-A1 BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D AMR TECHNOLOGY, INC. (US) 2006-08-24 WO disclosed
US-20060183769-A1 Benzoxazole carboxamides for treating CINV and IBS-D AMR TECHNOLOGY, INC. (US) 2006-08-17 US disclosed
US-7056937-B2 Sulfonylquinoxalone derivatives as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2006-06-06 US disclosed
EP-1501807-A1 SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS Elan Pharmaceuticals, Inc. (US) 2005-02-02 EP disclosed
US-20040147519-A1 Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2004-07-29 US disclosed
US-20040147520-A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2004-07-29 US disclosed
WO-2003093245-A1 SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS ELAN PHARMACEUTICALS, INC. (US) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293332-A1 Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists BDKRB2, BDKRB1, PDXK CTNNB1 4284/4885WNT3A 4229/4885HTR1B 516/4885
US-20040147519-A1 Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists BDKRB2, BDKRB1, HRH2 CTNNB1 4289/4885WNT3A 4228/4885HTR1B 872/4885
US-11246862-B2 Process for the preparation of lifitegrast LIFR, PTGFR, CSF1R CTNNB1 4079/4885WNT3A 1455/4885HTR1B 1434/4885
US-20060183769-A1 Benzoxazole carboxamides for treating CINV and IBS-D HTR3E, BRS3, HTR3A CTNNB1 2911/4885WNT3A 2950/4885HTR1B 43/4885
US-20040147520-A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists BDKRB2, BDKRB1, PDXK CTNNB1 4444/4885WNT3A 4413/4885HTR1B 882/4885
US-10183938-B2 Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors CHRNA7, CHRNA6, CHRNA5 CTNNB1 2186/4885WNT3A 2639/4885HTR1B 612/4885
US-20170369486-A1 GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS CHRNA7, CHRNA6, CHRNA5 CTNNB1 2396/4885WNT3A 2692/4885HTR1B 707/4885
US-20200306242-A1 NOVEL PROCESS FOR THE PREPARATION OF LIFITEGRAST LIFR, CSF1R, CSF3R CTNNB1 3806/4885WNT3A 1083/4885HTR1B 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.